Printer Friendly

Amunix Names You as CEO and Heyman as Chairman.

M2 PHARMA-January 7, 2019-Amunix Names You as CEO and Heyman as Chairman


- US-based biopharmaceutical company Amunix Pharmaceuticals Inc. has appointed Angie You, Ph.D., as chief executive officer, and Rich Heyman, Ph.D., as chairman of the board of directors, the company said.

Prior to joining Amunix, Dr. You served as chief business and strategy officer and head of commercial at Sierra Oncology (NASDAQ: SRRA), a hematology and oncology drug development company, where she helped the company through a successful initial public offering that raised over USD 150m.

She also led the company's strategic and transactional business and commercial efforts, including building its robust pipeline through acquisition and licensing of several product assets.

Prior to Sierra, Dr. You served as chief business officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company.

Dr. Rich Heyman is a scientist and biopharma executive with over 25 years of experience leading innovative biotechnology companies.

Heyman previously served as chief executive officer of Seragon Pharmaceuticals, a company focused on drugs targeting hormone dependent cancers that was acquired by Roche for an upfront payment of USD 725m and up to USD 1bn in contingent milestone payments.

Heyman was also the co-founder and chief executive officer of Aragon Pharmaceuticals, which was acquired for a total consideration of up to USD 1bn by Johnson and Johnson.

Prior to Aragon, Dr. Heyman held leading scientific and business roles at several biotechnology companies, including X-Ceptor Therapeutics and Ligand Pharmaceuticals.

At Ligand, Dr. Heyman led the development of Panretin and Targretin, which were approved by the FDA for the treatment of cancer.

In addition to serving on the Amunix Pharmaceuticals board of directors, Dr. Heyman is a director at Gritstone Oncology, Yumanity Therapeutics, Metacrine Inc., Vividion Therapeutics, Mavupharma, and ORIC Pharmaceuticals.

He is also the vice chairman of The Salk Institute and author or inventor of more than 120 publications and patents. Dr. Heyman was an NIH postdoctoral fellow at the Salk Institute and received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.

Amunix Pharmaceuticals, based in Mountain View, CA, is a privately held drug discovery and development company with two proprietary technologies, XTEN and ProTIA, that enable the rapid generation of protein therapeutics that are engineered to be fit for purpose.

The company's goal is to leverage its protein engineering platform and know-how to discover and develop safe and effective therapeutics for patients with cancer and other serious diseases.

Amunix's robust technology platforms have been validated through multiple collaborations with leading biopharmaceutical companies including Celgene, Genentech, Janssen, Roche, Bioverativ, and Baxter.

Founded in 1991, Frazier Healthcare Partners is a provider of growth and venture capital to healthcare companies.

With nearly USD 4.2bn total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies.

((Comments on this story may be sent to
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jan 7, 2019
Previous Article:Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome.
Next Article:Takeda Inks Multiple Cell Therapy Collaborations to Advance Novel Immuno-Oncology Portfolio.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |